Drugs / CART-meso
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03497819 | Oct 2017 → Oct 2019 | malignant pancreatic neoplasm | First Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02465983 | May 2015 → Sep 2017 | malignant pancreatic neoplasm | University of Pennsylvania | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02159716 | Jun 2014 → Nov 2015 | malignant epithelial tumor of ovary, malignant pleural mesothelioma, pancreatic ductal adenocarcinoma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARTmeso | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03497819 ↗ |
| Modality | Cell therapy | “CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.” NCT02159716 ↗ |
| Route | Intravenous | “intravenously administered lentiviral transduced CART-meso cells” NCT02159716 ↗ |